Abstract
The last fifteen years have witnessed impressive changes in our approach to patients with different haematological malignancies. These have largely stemmed from the continuous development of biotechnologies and from their progressive implementation in the clinical setting. In this brief review, we will highlight some of the areas (diagnosis, follow-up and treatment) in which biotechnologies have had an objective impact and will also underline how a close biologico-clinical integration, unparalleled in all other fields of oncology, is today mandatory for an up-to-date management of haematological malignancies.
| Original language | English |
|---|---|
| Pages (from-to) | 54-58 |
| Number of pages | 5 |
| Journal | FORUM - Trends in Experimental and Clinical Medicine |
| Volume | 9 |
| Issue number | 3 Suppl 3 |
| Publication status | Published - Jul 1999 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Biotechnologies in haematological malignancies. / Foà, R.; Reato, G.; Guarini, A.
In: FORUM - Trends in Experimental and Clinical Medicine, Vol. 9, No. 3 Suppl 3, 07.1999, p. 54-58.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Biotechnologies in haematological malignancies.
AU - Foà, R.
AU - Reato, G.
AU - Guarini, A.
PY - 1999/7
Y1 - 1999/7
N2 - The last fifteen years have witnessed impressive changes in our approach to patients with different haematological malignancies. These have largely stemmed from the continuous development of biotechnologies and from their progressive implementation in the clinical setting. In this brief review, we will highlight some of the areas (diagnosis, follow-up and treatment) in which biotechnologies have had an objective impact and will also underline how a close biologico-clinical integration, unparalleled in all other fields of oncology, is today mandatory for an up-to-date management of haematological malignancies.
AB - The last fifteen years have witnessed impressive changes in our approach to patients with different haematological malignancies. These have largely stemmed from the continuous development of biotechnologies and from their progressive implementation in the clinical setting. In this brief review, we will highlight some of the areas (diagnosis, follow-up and treatment) in which biotechnologies have had an objective impact and will also underline how a close biologico-clinical integration, unparalleled in all other fields of oncology, is today mandatory for an up-to-date management of haematological malignancies.
UR - http://www.scopus.com/inward/record.url?scp=0033155226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033155226&partnerID=8YFLogxK
M3 - Article
C2 - 10607847
AN - SCOPUS:0033155226
VL - 9
SP - 54
EP - 58
JO - FORUM - Trends in Experimental and Clinical Medicine
JF - FORUM - Trends in Experimental and Clinical Medicine
SN - 1121-8142
IS - 3 Suppl 3
ER -